Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.72 |
| ▸ | FAAH | O00519 | 5/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5868258 | 0.91 | ACHE (0.58) | ACHEFAAHCHRM2CHRM3 | |
| SCHEMBL5867951 | 0.89 | ACHE (0.55) | ACHEFAAHCHRM3BACE1 | |
| SCHEMBL5867983 | 0.87 | ACHE (0.54) | ACHEFAAHSMN1; SMN2 | |
| SCHEMBL5867969 | 0.86 | ACHE (0.52) | ACHEFAAHBACE1 | |
| SCHEMBL5868124 | 0.85 | ACHE (0.52) | ACHEFAAHCHRM2CHRM3BACE1 | |
| SCHEMBL5868059 | 0.84 | ACHE (0.51) | ACHEFAAHBACE1 | |
| SCHEMBL5867979 | 0.84 | ACHE (0.51) | ACHEFAAHCHRM2CHRM3SMN1; SMN2 | |
| SCHEMBL5867913 | 0.84 | ACHE (0.50) | ACHEFAAHCHRM3BACE1BCHE | |
| SCHEMBL5868101 | 0.84 | ACHE (0.50) | ACHEFAAHBACE1 | |
| SCHEMBL5867956 | 0.84 | ACHE (0.48) | ACHEFAAHBACE1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053078-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1289954-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6900196-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040259868-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-12-23 | — | — | US | disclosed |
| US-20030109706-A1 | Serine pretease inhibitors | ELI LILLY AND COMPANY | 2003-06-12 | — | — | US | disclosed |
| EP-1289954-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096303-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109706-A1 | Serine pretease inhibitors | PRSS1, SERPINE1, HPN | ACHE 2079/4885FAAH 652/4885CHRM2 3408/4885 |
| US-20040259868-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | ACHE 2174/4885FAAH 563/4885CHRM2 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.